Who is sponsoring NCT04338438?

NCT04338438 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT04338438?

Interventions in NCT04338438: Apatinib Mesylate tablets combined with S-1 capsules.

What condition does NCT04338438 study?

NCT04338438 studies Gastric Cancer.

Is NCT04338438 still recruiting?

NCT04338438 is currently completed. Last updated 10 November 2020.

Last reviewed 2020-11-10 · How we verify

NCT04338438

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Completed Phase 2 Last updated 10 November 2020

What this trial tests

Phase 2 trial testing Apatinib Mesylate tablets combined with S-1 capsules in Gastric Cancer in 37 participants. Completed in 31 January 2020.

Timeline

1 May 2015

Primary endpoint
30 April 2019

31 January 2020

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 May 2015
Primary completion	30 April 2019
Estimated completion	31 January 2020

Drugs / interventions tested

Apatinib Mesylate tablets combined with S-1 capsules — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Beijing Friendship Hospital

Who can join

18 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.
Xu D, Luo Y, Wang P, Li J, et al · · 2023 · cited 6× · PMID 37384288 · DOI 10.3389/fonc.2023.1148131
Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C, Bai Z, Zhang J, Jiang H, et al · · 2021 · cited 4× · PMID 34790371 · DOI 10.21037/jgo-21-186
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer.
Wu Z, Ni J, Xu Q. · · 2025 · PMID 41211418 · DOI 10.3389/fonc.2025.1654300

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04338438 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 10 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04338438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing